Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ovid Therapeutics Inc (NQ: OVID ) 0.8862 +0.0563 (+6.78%) Streaming Delayed Price Updated: 3:26 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ovid Therapeutics Inc < Previous 1 2 Next > eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures Today 8:00 EDT From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations July 01, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat June 17, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results May 14, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 13, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference April 04, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results March 08, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference February 28, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) December 01, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates November 03, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 October 18, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit October 10, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023 September 26, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference September 20, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Participate in Upcoming September Investor Conferences August 30, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates August 04, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023 August 01, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer June 28, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Added to Russell 3000® Index June 26, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates May 05, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors May 01, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting April 27, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference April 10, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results March 13, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum March 09, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures March 08, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference February 28, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments February 08, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial January 05, 2023 A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options From Ovid Therapeutics Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.